Kissei Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	19,358	25,169	22,894	25,893	30,013	20,456
Short-Term Investments	27,373	23,485	23,039	23,706	23,139	23,998
Cash & Short-Term Investments	46,731	48,654	45,933	49,599	53,152	44,454
Cash Growth	5.11%	5.92%	-7.39%	-6.69%	19.57%	-25.50%
Receivables	34,548	28,951	27,790	22,083	21,956	23,058
Inventory	26,834	24,979	26,296	22,798	18,987	20,118
Other Current Assets	3,455	4,396	4,532	6,161	5,247	5,335
Total Current Assets	111,568	106,980	104,551	100,641	99,342	92,965
Property, Plant & Equipment	29,801	27,069	24,861	24,579	24,074	24,290
Long-Term Investments	93,972	107,544	128,910	94,034	112,574	149,365
Goodwill	-	242	309	-	-	-
Other Intangible Assets	2,121	1,652	1,683	1,507	1,569	1,640
Long-Term Deferred Tax Assets	294	566	608	433	524	585
Other Long-Term Assets	21,851	1	2	1	1	2
Total Assets	259,607	244,059	260,929	221,200	238,087	268,861
Accounts Payable	9,023	4,602	4,893	4,617	4,104	7,909
Accrued Expenses	948	2,192	1,856	1,679	1,721	1,830
Short-Term Debt	1,270	1,280	1,340	1,490	1,640	1,743
Current Income Taxes Payable	4,023	1,474	2,380	408	3,497	1,487
Other Current Liabilities	9,041	7,030	7,194	6,763	7,782	5,276
Total Current Liabilities	24,801	16,578	17,663	14,957	18,744	18,245
Pension & Post-Retirement Benefits	216	202	209	192	181	1,398
Long-Term Deferred Tax Liabilities	16,283	16,481	21,188	10,426	16,259	28,480
Other Long-Term Liabilities	594	673	735	812	724	786
Total Liabilities	41,894	33,934	39,795	26,387	35,908	48,909
Common Stock	24,356	24,356	24,356	24,356	24,356	24,356
Additional Paid-In Capital	24,243	24,226	24,226	24,226	24,226	24,226
Retained Earnings	133,488	131,488	127,310	125,576	118,183	109,270
Treasury Stock	-15,513	-14,520	-13,209	-12,912	-12,912	-12,911
Comprehensive Income & Other	49,817	43,453	57,344	32,653	47,532	74,373
Total Common Equity	216,391	209,003	220,027	193,899	201,385	219,314
Minority Interest	1,322	1,122	1,107	914	794	638
Shareholders' Equity	217,713	210,125	221,134	194,813	202,179	219,952
Total Liabilities & Equity	259,607	244,059	260,929	221,200	238,087	268,861
Total Debt	1,270	1,280	1,340	1,490	1,640	1,743
Net Cash (Debt)	45,461	47,374	44,593	48,109	51,512	42,711
Net Cash Growth	5.28%	6.24%	-7.31%	-6.61%	20.61%	-26.25%
Net Cash Per Share	1084.97	1086.01	985.30	1043.24	1117.03	915.25
Filing Date Shares Outstanding	41.45	41.44	44.21	45.96	46.12	46.12
Total Common Shares Outstanding	41.45	42.81	44.21	46.12	46.12	46.12
Working Capital	86,767	90,402	86,888	85,684	80,598	74,720
Book Value Per Share	5220.27	4882.67	4977.38	4204.63	4366.94	4755.71
Tangible Book Value	214,270	207,109	218,035	192,392	199,816	217,674
Tangible Book Value Per Share	5169.10	4838.42	4932.32	4171.95	4332.92	4720.15
Order Backlog	-	3,403	2,613	2,098	1,479	2,726

Source: S&P Global Market Intelligence. Standard template. Financial Sources.